Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

All Myocarditis, Pericarditis Cases With COVID-19 Vaccines Now Must Be Reported To VAERS

Executive Summary

The change to three vaccine emergency use authorizations was made quietly, most recently for the Novavax vaccine.

You may also be interested in...



Is A Class-Wide Myocarditis Warning Coming For COVID-19 Vaccines?

Now that multiple vaccines using different platforms seem to be associated with heart inflammation, the FDA and others want more data on whether a common characteristic of the virus or vaccine manufacturing is related.

Novavax Gains US FDA Advisory Committee Endorsement, But So Does Myocarditis Risk Statement

Vaccines and Related Biological Products Advisory Committee members agree another option should be made available, especially if Novavax's protein-based design could encourage those who refused the mRNA vaccines to be inoculated.

mRNA COVID Vaccine Dosing Intervals May Be Extended To Mitigate Myocarditis Risk

While data suggests higher risk of myocarditis in young males receiving Moderna’s vaccine, US CDC advisory committee did not consider preferential recommendation. ACIP voted to recommend Spikevax for those 18 years and older following full FDA approval.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel